Securities Trading Policy
Released
Released
Announcement PDF
Securities Trading Policy
Avecho Biotechnology Limited
ACN 056 482 403
1.
Purpose
1.1
This Securities Trading Policy (Policy) sets out the requirements for directors, employees,
consultants and contractors of Avecho Biotechnology Limited (Avecho or Company) and its
related entities in relation to dealing in securities of Avecho Biotechnology Limited or any
other securities which may be affected by this policy or the law.
1.2
This Policy has important implications for all directors, officers, and employees. If you do not
understand the implications of this Policy or how it applies to you, you should raise the matter
with the Chief Executive Officer or the Company Secretary before trading in any securities
which may be affected by this Policy or the law.
1.3
This Policy extends to directors, officers, employees, or potential insiders (including such
parties as advisors and consultants who have access to or are involved with confidential
information). This includes a director, officer or employee of Company, the director’s, officer’s
or employee’s immediate family (includes a person or persons under the control or influence
of the director, officer or employee) and related entities controlled by the director, officer or
employee or members of the immediate family.
1.4
This Policy only provides a summary of applicable legal and regulatory issues which are
complex and should therefore only be used as a general guide and not as legal advice.
2.
Insider Trading
2.1
The Corporations Act 2001 prohibits Insider Trading.
2.2
If a person has information about securities and the person knows, or ought reasonably to
know, that the information is inside information, it is illegal for the person to:
(a)
deal in the securities;
(b)
procure another person to deal in the securities; or
(c)
give the information to another person (also known as “tipping”) who the person
knows, or ought reasonably to know, is likely to:
(i)
deal in the securities; or
(ii)
procure someone else to deal in the securities.
2.3
The insider trading prohibition extends to dealings by individuals through nominees, agents,
or other associates, such as family members, family trusts and family companies.
2.4
The prohibition does not apply to acquisitions of shares or options by employees made under
employee share or option schemes, nor does it apply to the acquisition of shares as a result of
the exercise of options under an employee option scheme. However, the prohibition does
apply to the sale of shares acquired under an employee incentive scheme (whether directly or
through the exercise of options).
2.5
Insider trading is a criminal offence. It is punishable by substantial fines and/or imprisonment
or both. A company may also be liable if an employee or director engages in insider trading.
2.6
Insider trading may also attract civil penalties. A court may impose substantial pecuniary
penalties for insider trading and order payment of compensation to persons who suffer loss
or damage because of insider trading.
Avecho Biotechnology Limited
1
Securities Trading Policy
3.
What is Insider Information?
3.1
Insider information is information that:
3.2
(a)
is not generally available; and
(b)
if it were generally available, would, or would be likely to, influence persons who
commonly invest in securities in deciding whether to acquire or dispose of the relevant
securities.
Information is generally available if it:
(a)
is readily observable;
(b)
has been made known in a manner likely to bring it to the attention of persons who
commonly invest in securities of the relevant type and a reasonable period for that
information to be disseminated has elapsed since it was made known; or
(c)
consists of deductions, conclusions or inferences made or drawn from information
falling under paragraphs above.
3.3
It does not matter how or where the person obtains the information – it does not have to be
obtained from the Company to constitute inside information.
4.
The Trading Policy
4.1
As a general rule, directors, officers and employees must not:
(a)
buy, sell or otherwise deal in Avecho securities whilst in possession of price sensitive
information;
(b)
advise, procure or encourage any other person to buy, sell or otherwise deal in Avecho
securities whilst in possession of price sensitive information;
(c)
pass on information to any person, if you know or ought to reasonably know that the
person may use the information to buy, sell or otherwise deal (or procure another
person to buy, sell or otherwise deal) in Avecho securities.
(d)
engage in short-term trading (less than one month), or short selling of the Company’s
securities at any time;
(e)
enter into margin lending or other secured financing arrangements in respect of the
Company’s securities; or
(f)
enter into transactions with securities (or any derivative thereof) which limit the
economic risk of any unvested entitlements awarded under an equity-based
remuneration scheme, or otherwise awarded, or which will be offered by the
Company in the future (e.g. hedging).
5.
Company Securities
5.1
Directors or officers are to obtain prior written approval from the Chair of the Board (and the
Chair is required to confirm with the Chief Executive Officer that there is no market sensitive
information that has not been released), or in his or her absence the Chief Executive Officer,
at least one day prior to the purchase / sale of securities in Avecho held by the director or
officer. Should the Chair wish to purchase / sell securities he or she shall similarly notify the
Chief Executive Officer and/or the Company Secretary the at least one day prior to sale.
Avecho Biotechnology Limited
2
Securities Trading Policy
5.2
Employees or potential insiders are to obtain prior written approval from the Chief Executive
Officer or in his or her absence, the Company Secretary, at least one day prior to the purchase
/ sale of securities in Avecho held by the employee.
5.3
A director, officer or employee shall not trade securities in Avecho if the director, officer or
employee is aware of any information concerning Avecho which has not been made public
and/or which if made public, a reasonable person would expect to have a material impact on
the price or value of Avecho securities. Employees must inform the Chief Executive Officer of
all market sensitive (material) information immediately after they become aware of it.
5.4
If the Chair of the Board has received a request for either a sale or purchase of securities in
Avecho he is required to confirm in writing with the Chief Executive Officer or in his or her
absence the Company Secretary that there is no market sensitive information that has not
been released.
5.5
Unless otherwise advised by the Chair of the Board or the Chief Executive Officer (as required),
where such approval is obtained, training must occur within seven (7) business days.
6.
Closed Periods
6.1
The following periods are considered a Closed Period and directors, officers and employees
must not trade in the Company securities:
(a)
the period 30 days immediately preceding the announcement of the Company’s half
year and annual accounts and ending 48 hours after such release; or
(b)
any other periods advised by the Company.
7.
Definition
7.1
This Policy extends to directors, officers, employees or potential insiders (including such
parties as advisors and consultants who have access to or are involved with confidential
information). This includes a director, officer or employee of Avecho, the director’s, officer’s
or employee’s immediate family (includes a person or persons under the control or influence
of the director, officer or employee) and related entities controlled by the director, officer or
employee or members of the immediate family.
8.
Exceptional Circumstances in which Trading in a Closed Period is Permitted
8.1
For the purpose of this Policy, the following dealing in securities is permitted during a closed
period:
(a)
transfers of securities where the beneficial ownership of the securities does not
change, e.g. the transfer of securities already held into a superannuation fund where
the person is the major beneficiary;
(b)
the exercise of an option or a right, or the conversion of a convertible security, where
the final date to exercise the option or right, or convert the security, falls during a
prohibited period;
(c)
undertakings to accept, or acceptance of, takeover offers; and
(d)
trading under an offer or invitation made to all or most of the Company’s security
holders such as a rights issue, security purchase plan, a dividend reinvestment plan or
securities buy back.
(e)
Financial hardship:
Avecho Biotechnology Limited
3
Securities Trading Policy
i.
A person may be in severe financial hardship if they have a pressing financial
commitment that cannot be satisfied other than by selling the securities of
the Company.
ii.
In the interests of an expedient and informed determination by the Chair (or
all other members of the Board as the context requires), any application for
an exemption allowing the sale of Company securities in a Closed Period or a
Prohibited Period based on financial hardship must be made in writing stating
all of the facts and be accompanied by copies of relevant supporting
documentation, including contact details of the person’s accountant, bank
and other such independent institutions (where applicable).
iii.
Any exemption, if issued, will be in writing and shall contain a specified time
period during which the sale of securities can be made.
8.2
Persons who are not in the possession of price sensitive information, may be given prior
written clearance by the Chairperson to sell or otherwise dispose of Avecho securities during
a prohibited period, where the person is in severe financial difficulties or other exceptional
circumstances determined by the Board, such as required under a court order, in a bona fide
family settlement, or some other overriding legal or regulatory requirement to do so.
9.
Other Securities
9.1
A director, officer or employee shall not trade securities of another company where the
director, officer or employee is aware:
(a)
non-public information regarding investigations or negotiations being conducted by
Avecho or any of its related entities into that company; and/or
(b)
non-public material information of a company in partnership with Avecho.
10.
Breach of Policy
10.1
A breach of this Policy by a director, officer or employee may lead to disciplinary action. It may
also be a breach of the law.
11.
ASX Notification for Directors
11.1
The ASX Listing Rules require the Company to notify the ASX within 5 business days after any
dealing in securities of the Company (either personally or through an Associate) which results
in a change in the relevant interests of a Director in the securities of the Company. The
Company has made arrangements with each Director to ensure that the Director promptly
discloses to the Company Secretary all the information required by the ASX.
11.2
Directors are also required to comply with the Corporations Act and must notify under that
Act within 2 business days if they begin to have, or cease to have, a ‘substantial holding’ in the
Company or if they already have a ‘substantial holding’ in the Company and there is a
movement of at least 1% in their holding.
12.
Assistance and Additional Information
12.1
Any questions about this Policy should be directed to the Company Secretary.
Avecho Biotechnology Limited
4
Securities Trading Policy
13.
Approved and Adopted
13.1
This Policy was approved and adopted by the Board on 27 August 2020.
Avecho Biotechnology Limited
5
Securities Trading Policy
Share your feedback
Discover